ВОЗМОЖНОСТИ КАРДИОЛОГА В БОРЬБЕ С ИНСУЛЬТОМ: КОМПЛЕКСНАЯ ТЕРАПИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ (МЕСТО АНТАГОНИСТОВ КАЛЬЦИЯ)
https://doi.org/10.15829/1728-8800-2013-4-79-81
Аннотация
Статья посвящена современной проблеме кардиоцеребральных отношений, сочетанной сердечно-сосудистой патологии, которая требует комплексного подхода. В профилактике инсульта – традиционно неврологической проблемы, основная роль принадлежит кардиологу, который имеет возможность модифицировать многие факторы риска. Лечение артериальной гипертензии – важнейший шаг, и среди всего множества антигипертензивных средств особое место занимают антагонисты кальциевых каналов новых поколений.
Об авторе
Е. О. Таратухин
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова, Москва
Россия
Россия
кардиолог, к. м.н., ассистент кафедры госпитальной терапии № 1 лечебного факультета
Тел.: +7 (916) 637-29-78
Список литературы
1. Mathers CDC, Mernard KM, Iburg M, et al. Estimated Age Standardized Death Rate, Cerebrovascular Disease (2004). Stroke: Oxford Neurology Library (ed. Hennerici MG, Binder J). OUP 2013; p. 4.
2. Hennerici MG, Binder J (ed.). Stroke: Oxford Neurology Library. OUP 2013; 192 p.
3. Norrving B, Kissela B. The global burden of stroke and need for a continuum of care. Neurology 2013; 80 (Suppl 2): 5–12/
4. Floras JS. Blood pressure variability: a novel and important risk factor. Can J Cardiol 2013; 29 (5): 557–63.
5. Sajjad A, Chowdhury R, Felix JF, et al. A systematic evaluation of stroke surveillance studies in low- and middle-income countries. Neurology 2013; 80 (7): 677–84.
6. Gupta AK, Arshad S, Poulter NR. Compliance, Safety and Effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010; 55: 399–407.
7. Messerli FH. Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid Based Med 2008; 13: 18–22.
8. Armario P, Waeber B. Therapeutic strategies to improve control of hypertension. J Hypertens 2013; Suppl1: 9–12.
9. Hoyer J. Non-pharmacological and pharmacological treatment of arterial hypertension: current situation. Herz 2012; 37 (7): 728–34.
10. Chen GJ, Yang MS. The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials. PLoS One 2013; 8 (3): e57854.
11. Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013; 381 (9866): 537–45.
12. Libby P, Bonow RO, Mann DL, et al. Braunwald’s Heart Disease (8th ed.). Elsevier 2008; 2274 p. – p.1061.
13. Sakurai-Yamashita Y, Harada N, Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Noll Neurobiol 2011; 31 (4): 561–7.
14. Sansanayudh N, Wongwiwatt S, Veerayuth S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai 2010; 93: 84–92.
15. Yeh JL, Hsu JH, Liang JC, et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharideinterferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis 2013; 226 (2): 364–72.
16. Farah R, Khamisy-Farah R, Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol 2013; 32: 85–93.
17. Borghi C. Lercanidipine in hypertension. Vasc Health & Risk Manag 2005; 1: 173–82.
18. Rossignol P, Kessler M, Zannad F. Visit-to-visit blood pressure variability and risk for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 2013; 22 (1): 59–64.
19. Ostroumova OD. The variability of arterial pressure and risk of stroke in hypertension. Zh Nevrol Psikhiatr im SS Korsakova 2012; 112 (10): 45–50. Russian (Остроумова О. Д. Вариабельность артериального давления и риск развития инсульта при гипертонической болезни. Ж неврологии и психиатрии им. С. С. Корсакова 2012; 10: 45–50).
20. Czaja-Mitura I, Bortkiewicz A. Ambulatory blood pressure monitoring and its usefulness in occupational medicine. Med Pr 2012; 63 (6): 701–9.
21. Asayama K, Kikuya M, Schutte R, et al. Home blood pressure variability as cardiovascular risk factor in the population of Ohasama. Hypertension 2013; 61 (1): 61–9.
22. Karas M, Lacourciere Y, LeBlanc AR, et al. Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J Hypertens 2005; 23 (6): 1251–60.
23. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta-blockers and calcium-channel blockers on within-individual variability in blood pressure and rick of stroke. Lancet Neurol 2010; 9 (5): 469–80.
24. Matsui Y, O’Rourke MF, Hoshide S, et al. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension 2012; 59 (6): 1132–8.
25. Ogura C, Ono K, Miyamoto S, et al. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension. Blood Pres 2012; 21 (6): 367–71.
Рецензия
Для цитирования:
Таратухин Е.О. ВОЗМОЖНОСТИ КАРДИОЛОГА В БОРЬБЕ С ИНСУЛЬТОМ: КОМПЛЕКСНАЯ ТЕРАПИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ (МЕСТО АНТАГОНИСТОВ КАЛЬЦИЯ). Кардиоваскулярная терапия и профилактика. 2013;12(4):79-81. https://doi.org/10.15829/1728-8800-2013-4-79-81
For citation:
Taratukhin E.O. STROKE PREVENTION OPPORTUNITIES FOR CARDIOLOGISTS: COMPLEX MANAGEMENT OF ARTERIAL HYPERTENSION (ROLE OF CALCIUM ANTAGONISTS). Cardiovascular Therapy and Prevention. 2013;12(4):79-81. (In Russ.) https://doi.org/10.15829/1728-8800-2013-4-79-81
Просмотров: 527
Послать статью по эл. почте 
